Skip to content
naulon
Not checkedNot checked for notices yet.

Expression levels of MIF, NLRP1 and FOXP3 genes along with biomarker levels in patients with active form of non-segmental generalized vitiligo: A study in South Indian population

Alokananda Chakraborty, Seelamneni Thulasamma, Shravan Kumar Ghali and 8 more

Songklanakarin Journal of Science and Technology (SJST) · 2022

doi:10.14456/sjst-psu.2022.50 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Vitiligo, the most widespread hypopigmentary syndrome, is considered to be a multifactorial disease in which the active melanocytes are lost. Vitiligo has been studied in a variety of ways, and several genes have been implicated. In this study we focused on investigating biomarker levels of TNF-α, MDA and TAS by using ELISA, and along with that mRNA expression levels of MIF, NLRP1 and FoxP3 genes were quantified with qRT-PCR. In expression studies, Non-segmental Generalized Vitiligo (NSV) subjects had a substantial (P <.05) fold change in MIF gene expression compared to healthy subjects, with a 0.7 change in expression level. In FoxP3 and NLRP1, however, there was just an 0.3-fold change in expression. However, there was a substantial increase (P <.01) in TNF-α and (P <.0005) in TAS levels, but no difference in Malondialdehyde levels (MDA). The current study is a baseline study suggesting that MIF, with a 0.7-fold change, may play a key role in the pathogenesis of active NSV subjects, while changes in NLRP1 and FoxP3 mRNA expression levels were weaker. We also found a significant increase (P <.01) in TNF-α and (P <.0005) in TAS levels, which may be noted as a key feature in Vitiligo subjects.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.